

JUBILANT PHARMA LIMITED
(Company Registration No. 200506887H)
(Incorporated in the Republic of Singapore)
Registered office: 80 Robinson Road, #02-00, Singapore 068898

ANNOUNCEMENT

**Jubilant Pharma Limited to fully redeem the remaining outstanding amount of
4.875% Senior Notes Due 2021
ISIN Number: XS1493722299
Common Code: 149372229**

February 3, 2021

Singapore Exchange Securities Trading Limited
11 North Buona Vista Drive #06-07
The Metropolis Tower 2
Singapore 138589

Dear Sirs,

Jubilant Pharma Limited (the “**Company**”) wishes to announce that it has given notice to the holders of its US\$300,000,000 4.875% Senior Notes due 2021 (the “**Notes**”) that it has elected to exercise its option to redeem US\$100,000,000 in aggregate principal amount of the Notes on March 5, 2021 (the “**Redemption Date**”) pursuant to the terms of the indenture dated as of October 6, 2016 (the “**Indenture**”) between the Company and The Bank of New York Mellon, London Branch as trustee, governing the Notes. The Company had made the first early redemption of US\$100,000,000 in November 2019 and the second early redemption of US\$100,000,000 on January 29, 2021, and following the proposed redemption of US\$100,000,000 on March 5, 2021, the Notes will be paid in full and no amount will remain outstanding under the Notes.

Pursuant to the terms of the Indenture, the redemption price for the outstanding amount of the Notes will be equal to 101.21875% of the principal amount of such Notes, plus accrued and unpaid interest thereon, to (but not including) the Redemption Date (the “**Redemption Price**”). The payment of the Redemption Price in respect of the Notes called for redemption will occur via the standard procedures of Euroclear and Clearstream. The Notes called for redemption will be cancelled by the Company upon redemption.

Thanking you,

Yours faithfully,

For Jubilant Pharma Limited

Sd/-

Shyam S. Bhartia
Chairman and Managing Director